A5019978374- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- BRCA gene mutations in cancer
- Cancer survivorship and care
- Breast Lesions and Carcinomas
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- Lung Cancer Treatments and Mutations
- Chemotherapy-induced cardiotoxicity and mitigation
- DNA Repair Mechanisms
- Cancer Risks and Factors
- Brain Metastases and Treatment
- Cancer Immunotherapy and Biomarkers
- PI3K/AKT/mTOR signaling in cancer
- Global Cancer Incidence and Screening
- Colorectal Cancer Treatments and Studies
- Cancer Diagnosis and Treatment
- Patient-Provider Communication in Healthcare
- Palliative Care and End-of-Life Issues
- PARP inhibition in cancer therapy
- Breast Implant and Reconstruction
- Ethics in Clinical Research
- Cancer-related cognitive impairment studies
Case Western Reserve University
2008-2024
University Hospitals Seidman Cancer Center
2011-2023
University Hospitals of Cleveland
2005-2021
Case Comprehensive Cancer Center
1985-2021
University Hospitals Cleveland Medical Center
2008-2020
Mayo Clinic in Arizona
2019
Grand Charleroi Hospital
2019
Université Libre de Bruxelles
2019
Institut Jules Bordet
2019
University of Colorado Denver
2019
Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) –positive primary breast cancer triaged to chemotherapy when protein encoded by MKI67 gene (Ki67) level was > 10% after 2 4 weeks of neoadjuvant aromatase inhibitor (AI) therapy. A second objective examine risk relapse using Ki67-based Preoperative Endocrine Prognostic Index (PEPI). Methods The American College Surgeons Oncology Group (ACOSOG) Z1031A trial enrolled postmenopausal women with stage II...
Estrogen deprivation therapy with aromatase inhibitors has been hypothesized to paradoxically sensitize hormone-receptor-positive breast cancer tumor cells low-dose estradiol therapy.To determine whether 6 mg of (daily) is a viable for postmenopausal women advanced inhibitor-resistant hormone receptor-positive cancer.A phase 2 randomized trial vs 30 oral used daily (April 2004-February 2008 [enrollment closed]). Eligible patients (66 randomized) had metastatic treated an inhibitor...
The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations common physical psychosocial consequences of cancer to help healthcare professionals who work with survivors adult-onset in the posttreatment period. This portion guidelines describes regarding management anthracycline-induced cardiotoxicity lymphedema. In addition, immunizations prevention infections are included.
Distant metastases are present in 6% or more of patients with newly diagnosed breast cancer. In this context, locoregional therapy for the intact primary tumor has been hypothesized to improve overall survival (OS), but clinical trials have reported conflicting results.
Purpose/Objectives: To explore the use of virtual reality as a distraction intervention to relieve symptom distress in women receiving chemotherapy for breast cancer.
Background. Malignant tumors of the salivary glands make up approximately 5% head and neck cancers. The Eastern Cooperative Oncology Group (ECOG) initiated a phase II evaluation paclitaxel in patients with locally recurrent or metastatic gland malignancies. Methods. Chemo-naive histologically confirmed carcinoma origin (mucoepidermoid, adenocarcinoma, adenoid cystic) were eligible. Patients treated paclitaxel, 200 mg/m2 IV, every 21 days for minimum four cycles. Results. Forty-five treated....
Many cancer survivors experience menopausal symptoms, including female taking aromatase inhibitors or with a history of oophorectomy chemotherapy, and male who received are receiving androgen-ablative therapies. Sexual dysfunction is also common in survivors. menopause-related symptoms can increase distress have significant negative impact on quality life. This portion the NCCN Guidelines for Survivorship provide recommendations screening, evaluation, treatment sexual to help healthcare...
LBA2 Background: About 6% of newly diagnosed breast cancer patients present with Stage IV disease and an intact primary tumor (IPT). Locoregional treatment (LRT) for the IPT is hypothesized to improve survival based on retrospective analyses, but randomized trials have provided conflicting data. We now report results E2108, a Phase 3 trial that examined worth LRT following initial systemic therapy. Methods: were registered, treated optimal therapy (OST) patient characteristics; those who did...
The combination of lapatinib and trastuzumab has been observed to have a synergistic, antiproliferative effect against ErbB2-positive breast cancer cells in vitro. This phase I study assessed the safety, clinical feasibility, optimally tolerated regimen (OTR), pharmacokinetics (PK), preliminary activity this patients with advanced cancer.Cohorts three were treated escalating doses (750 1,500 mg) administered once daily (continuous) (4 mg/kg loading dose then 2 weekly) determine OTR. Once OTR...
Taxanes have effects on angiogenesis causing difficulties in separating biological of chemotherapy from those due to inhibitors. This randomized phase II trial was designed evaluate the additional biomarker effect when bevacizumab is added docetaxel.Patients with inoperable breast cancer were either 2 cycles preoperative docetaxel (D) 35 mg/m(2) i.v. weekly for 6 weeks, followed by a 2-week break; or 10 mg/kg every other week total 16 weeks (DB). Plasma and serum markers endothelial damage,...
The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations common consequences of cancer treatment. They are intended to aid health care professionals who work with survivors adult-onset in the posttreatment period, including those general oncology, specialty survivor clinics, primary practices. Guidance is also provided help promote physical activity, weight management, proper immunizations survivors. This article summarizes panel's discussions 2016...
Background: Decision aids are tools that help patients make specific and deliberative choices among options. This study was a group randomized controlled trial of novel decision aid to with breast cancer adjuvant therapy (AT) decisions. Methods: Fourteen oncology practices (n=58 physicians) were receive the or control pamphlet. Complete data obtained from 405 patient–oncologist pairs. Eligible had stage I–III disease completed their primary treatment. The is simple use computer program,...
1082 Background: Patients (pts) with triple negative breast cancer (TNBC) residual disease after neoadjuvant therapy have a high risk of recurrence. Methods: Pts BRCA mutations and/or TNBC lymph node (LN) or > 2 cm invasive anthracycline (A) taxane (T) were assigned 1:1 to cisplatin (C: 75 mg/m2D1 q3 wks x 4) +/- rucaparib (R: 24-30 mg IV D1,2,3 4 followed by R 30 100 orally wkly for 24 wks). BROCA analysis identified deleterious germline mutations. Pharmacokinetic sampling assess exposure...
Abstract: Whether cosmetically acceptable tumor-free (≥2 mm) surgical margins reduce the local-regional recurrence risk for patients treated with fractionated radiation therapy, chemotherapy, and hormonal therapy is unknown. The benefit of a minimum margin remains speculative because no contemporary studies have investigated extent invasive disease infiltration within breast beyond primary tumor. To address these clinical issues, we conducted retrospective study 341 women diagnosed stage I...
559 Background: Lapatinib is a selective and highly potent dual, competitive inhibitor of ErbB1 ErbB2 tyrosine kinases leading to cell growth arrest and/or apoptosis in dependent tumor lines xenografts. Combining two ErbB2-targeted therapies, e.g., anti-ErbB2 antibody with small molecule kinase inhibitor, that act at different sites the receptor distinct mechanisms action, may enhance efficacy both drugs. Methods: Patients (pts) metastatic breast cancer overexpress protein 2+ or 3+ were...
We used inflammatory breast cancer (IBC) as a model disease to investigate biological changes associated with an antiangiogenesis agent, SU5416, combined doxorubicin.Patients stage IIIB or IV IBC were treated neoadjuvantly the combination of SU5416 and doxorubicin for induction therapy. The dose (administered on days 1 4, every 3 weeks) day escalated in cohorts three patients starting at 110 60 mg/m2, respectively, total five cycles leading up mastectomy. Patients underwent serial assessment...
Abstract Patients with triple-negative breast cancer (TNBC) who have residual disease after neoadjuvant therapy a high risk of recurrence. We tested the impact DNA-damaging chemotherapy alone or PARP inhibition in this high-risk population. TNBC deleterious BRCA mutation (TNBC/BRCAmut) had >2 cm invasive persistent lymph node (LN) involvement were assigned 1:1 to cisplatin rucaparib. Germline mutations identified BROCA analysis. The primary endpoint was 2-year disease-free survival (DFS)...
1019^ Background: Patients (pts) with triple negative breast cancer (TNBC) who have residual disease after preoperative chemotherapy a high risk of recurrence. No standard systemic therapy has proven benefit. Data suggest that some pts TNBC and/or BRCA mutations may be sensitive to DNA-damaging and PARP inhibition. Methods: Eligible or known had lymph node involvement > 2 cm invasive anthracycline taxane neoadjuvant were assigned 1:1 postoperative cisplatin (C: 75 mg/m2D1 q3 wks x 4) +/-...